Indivior (LSE: INDV) has entered into a license agreement with fellow British company C4X Discovery Holdings (AIM: C4XD) to acquire exclusive global rights to develop and commercialize C4X's oral Orexin-1 receptor antagonist program for the treatment of addiction.
Under the terms of the agreement, C4XD will receive an upfront payment of $10 million and could receive up to $284 million of potential development, regulatory and commercialization milestones in addition to royalties. In turn, Indivior receives a global and exclusive licence to C4X3256 and all other compounds in the same patent family and is responsible for the cost and execution of all further development of C4X3256. The agreement covers the development of Orexin-1 antagonists for multiple indications.
The news, which is the first major partnership for the UK firm, had a staggering effect on C4D’s shares, which leapt as much as 136% to a high of 150 pence in early trading, and were still up 107% at 117 pence by mid-afternoon.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze